Navigation Links
UC Davis researchers identify a protein that may help breast cancer spread, beat cancer drugs
Date:4/1/2009

(SACRAMENTO, Calif.) New research from UC Davis Cancer Center shows that a protein called Muc4 may be the essential ingredient that allows breast cancer to spread to other organs and resist therapeutic treatment. The study, which appears in the April 1 issue of Cancer Research, is one of the first to characterize the role of Muc4 in the disease.

Kermit Carraway, senior author of the study, knew that Muc4 was not always expressed in primary breast cancer tumors, yet it could be present in lymph node metastases. He suspected that it may have a specialized function in the process of metastasis.

"Breast cancer deaths are caused by metastasis, not by the primary tumor," explained Carraway, an associate professor of biochemistry and molecular medicine. "It's at that point that the disease also becomes difficult to treat. We think that Muc4 may be packing a one-two punch by promoting the release of breast cancer cells from the primary tumor and then inhibiting their death."

Muc4 is member of a group of proteins called mucins, which are commonly found in fluids such as tears and mucus. They have a known role in protecting epithelial cells, from which breast cancer cells are derived. When separated from their surrounding cell matrix, epithelial cells tend to die. Metastasizing breast cancer cells, however, can survive this detachment.

"Because breast cancer cells can lose their adhesive properties and still thrive, we suspected that Muc4 may be somehow allowing them to leave their cellular framework, travel to secondary sites and withstand treatment," Carraway explained.

To test his suspicions, Carraway and his team conducted two experiments. They started by comparing breast cancer cells that express Muc4 with those for which Muc4 production is blocked. The researchers then exposed both types of cells to chemotherapy drugs. The Muc4-producing cells survived.

They repeated the experiment with breast cancer cells and epithelial cells that do not naturally express Muc4 but were engineered to do so. Both sets of cells avoided cell death and effectively resisted chemotherapy.

"Our results lead us to believe that Muc4 is somehow disrupting normal links between epithelial cells," said UC Davis graduate student Heather Workman, lead author of the study. "We now need to refine our understanding of this disruption process in order to find ways to interfere with it. There currently are no drugs that target Muc4, and this research will help change that."

Carraway is now preparing to test metastasizing breast cancer tumor cells for the overexpression of Muc4.

"If we find that Muc4 is all over metastasizing breast cancer cells, it will confirm that we are on the right track," he said.

While Carraway's current focus is on breast cancer, his findings could have relevance to other cancers that show aggressive properties. For example, Muc4 is also expressed in pancreatic, lung and ovarian tumor cells.

"Muc4 is likely a central cellular mechanism for metastasis of many cancers, and we will be continuing this important work to prove that," he said.


'/>"/>

Contact: Karen Finney
karen.finney@ucdmc.ucdavis.edu
916-734-9064
University of California - Davis - Health System
Source:Eurekalert

Related biology news :

1. UC Davis bench-to-bedside research: Promising treatment in clinical trials
2. UC Davis research shows that newly discovered drug reduces heart enlargement
3. UC Davis researchers find molecule that targets brain tumors
4. UC Davis discovery offers hope for treating kidney cancer
5. UC Davis team refines cancer treatments to reduce potential nerve damage
6. UC Davis researchers exploring gene therapy to fight AIDS
7. UC Davis researchers discover Achilles heel in pancreatic cancer
8. UC Davis researchers discover a key to aggressive breast cancer
9. UC Davis chemical ecologist wins major award
10. UC Davis researchers discover new drug target for inflammatory disease
11. UC Davis researchers define characteristics, treatment options for XXYY syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... Dec 15, 2016 ... Research and Markets has announced the addition of ... The report forecasts the global military biometrics market to ... The report has been prepared based on an in-depth market analysis ... its growth prospects over the coming years. The report also includes a ...
(Date:12/15/2016)... "Increase in mobile transactions is driving the ... market is expected to grow from USD 4.03 billion ... a CAGR of 29.3% between 2016 and 2022. The ... demand for smart devices, government initiatives, and increasing penetration ... is expected to grow at a high rate during ...
(Date:12/8/2016)... 2016  Singulex, Inc., the leader in Next Generation ... a license and supply agreement with Thermo Fisher Scientific, ... Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), a ... used to diagnose systemic bacterial infection and sepsis and ... aid in assessing the risk of critically ill patients ...
Breaking Biology News(10 mins):
(Date:1/11/2017)... , ... January 11, 2017 , ... ... scientific grants to ground-breaking microbiome studies. Its most recent microbiome impact grant award ... who will study the effect of long-term use of oral antibiotics, prescribed for ...
(Date:1/11/2017)... , ... January 11, 2017 , ... ... make all the difference when navigating the challenges young businesses face. With the ... the extensive expertise and experience of Geoff DiMasi, Founder and Principal of interactive ...
(Date:1/11/2017)... ... January 11, 2017 , ... Back pain relief technology is now available ... Surgery for positive back pain relief for WAR members. , This spinal restoration platform ... be life changing for millions suffering from chronic back pain. , What A ...
(Date:1/11/2017)... and BENGALURU, India , Jan. ... Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced ... accepted Mylan,s biologics license application (BLA) for MYL-1401O, a ... This product is a proposed biosimilar to branded trastuzumab, ... The anticipated FDA goal date set under the Biosimilar ...
Breaking Biology Technology: